相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre et al.
LANCET ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic Acid (TSU-68)
Ryuichi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
Novel advancements in the management of hepatocellular carcinoma in 2008
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats
Ryuichi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2007)
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
Ronnie T. P. Poon et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma
Roberta Pang et al.
CANCER LETTERS (2006)
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis
E Naumova et al.
CLINICAL CANCER RESEARCH (2006)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Opportunities for targeted therapies in hepatocellular carcinoma
MB Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies
BC Kuenen et al.
CLINICAL CANCER RESEARCH (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma
Joanna W. Ho et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma
DM O'Hanlon et al.
EUROPEAN JOURNAL OF CANCER (2002)
Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery
D Alexiou et al.
EUROPEAN JOURNAL OF CANCER (2001)
分享论文
